article thumbnail

Three Strategies to Optimize Healthcare Provider Networks in New and Existing Markets

Clarify Health

Here are our top three provider network optimization strategies for health plans seeking to gain market share and manage claims spend in 2023 and beyond. Use healthcare provider data to boost network performance Assessing provider performance is one of the key challenges of network design and optimization.

article thumbnail

Do healthcare mergers and acquisitions lead to better care for patients?

Clarify Health

Today’s healthcare providers are seeing significantly more patients than they did a decade ago – many of whom are often sicker and have more complex care needs. There is division in the healthcare industry over the pros and cons of healthcare mergers and acquisitions.

Leads 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Healthcare Watch November 2022

PM360

After surveying 2,005 nationally representative Americans, PatientPoint found that more than half are too afraid to ask their healthcare provider about their health condition or symptoms, with men even more afraid of these interactions than women (57% vs. 45%).

article thumbnail

PM360 2022 Trailblazer Awards Marketing Team of the Year Silver Winner the Wegovy Brand Team

PM360

Laura Nilsen, Global Product Lead, Obesity Marketing. Maximilian Jonathan Krawinkel, Global Product Lead, Obesity Marketing MCE. HCP Team Members: Aneil Batra, Vice President, Obesity Commercial Lead, Cardiometabolic Marketing. Christine Szymanski, Consumer Marketing Lead, Obesity Marketing. Novo Nordisk U.S.

article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers (2).

article thumbnail

Getting ahead of regulatory changes around PFAS in pharmaceutical packaging

Clarivate

1] To mitigate the potential presence of nitrosamine impurities in pharmaceuticals, manufacturers are now facing impending regulatory requirements in various markets – in the European Union, for example, they were obligated to submit reformulation strategies and mitigation plans in late 2022. [2].

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

Survival of the fittest: Biotech reset “Horrible” and “carnage” were how some described the early 2022 environment for biotech financing, as funding fell significantly below the highs of 2020 and 2021, and IPOs all but dried up. The second half of 2023 is likely to see a rebound from the trough of 2022, but it will be slow.